PHRX

PharmaDrug completes key milestone to support cGMP production of lead candidate PD-001

PharmaDrug Inc (CSE: PHRX) has laid the groundwork to support multi-kilogram production of cepharanthine-2HCL for use in the final drug production of PD-001 to treat responsive cancers and COVID-19. PD-001 is the Toronto-based pharmaceutical company’s patented, oral, and bioavailable version of cepharanthine – a natural product and an approved drug used for more than 70 […]